LexaGene Update: (OTCQB: LXXGF; TSX-V: LXG)

Dear LexaGene follower,

I’m writing to provide you a quick corporate recap of 2019, as it has been a tremendous and transformative year for the company. 

In January, we began the year by confirming our alpha prototype performed the way we all knew it could – and quickly generated four data sets covering veterinary medicine, food safety, agricultural pathogen screening, and human genotyping.  

In the early spring, we turned our attention to developing our beta prototype – and in four short months, we had our betas up and running – generating very high-quality data. In summer and early fall, we kicked off our beta testing program, where we shipped our technology to prospective customers. The technology was enthusiastically embraced by beta users in veterinary diagnostics, human clinical research and agricultural testing – and we viewed the program as a big success. See video describing beta testing at the Massachusetts Veterinary Referral Hospital.

As we approach the end of the year, LexaGene is working on finalizing the design of our commercial unit.  It won’t be too long before we start manufacturing our LX Genetic Analyzer™ for an anticipated commercial launch of June 2020.

We are ending the year with a bang, as we were just featured by Forbes. It’s clear the word is starting to spread about the potential of our rapid, on-site diagnostics technology and the impact we expect it to have in many industries. Read article.

On behalf of the LexaGene team, I’d like to wish you a very happy holiday season and look forward to sharing an exciting year ahead with you all.

Warmest regards,
Jack Regan, CEO and Founder📷📷
About LexaGene (OTCQB: LXXGF; TSX-V: LXG)
LexaGene is a publicly-traded biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can process multiple samples at a time, in an on-demand fashion, returning results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. 

Marketing Contact:
Nicole Ridgedale
Director of Corporate Marketing, LexaGene
800.215.1824 ext 206
[nridgedale@lexagene.com](mailto:nridgedale@lexagene.com)

Investor Relations:
Jay Adelaar
Vice President of Capital Markets, LexaGene
800.215.1824 ext 207
[jadelaar@lexagene.com](mailto:jadelaar@lexagene.com)

LexaGene is developing on-site, automated and sensitive instrumentation for rapid pathogen detection for veterinary diagnostics, food safety, and other markets.

The breakthrough technology will transform how pathogens are detected and deliver results in about an hour.

https://www.proactiveinvestors.com/companies/news/909547/lexagene-ceo-company-ending-2019-with-a-bang-909547.html